Physician profile
Muhammad Alsayid
NPI 1326356411
$3,222.94
in general payments reported to CMS, 2019-2025
20 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2021: $148 · 2022: $133 · 2023: $1,078 · 2024: $670 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156 · Travel and Lodging: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.37 |
| Travel and Lodging | $676.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $933.16 | 2023 | Gi Genius |
| Takeda Pharmaceuticals U.S.A., INC. | $390.78 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.82 | 2022-2025 | Trulance, Xifaxan |
| Madrigal Pharmaceuticals | $242.74 | 2025 | Rezdiffra |
| Abbvie INC. | $232.51 | 2024-2025 | |
| Olympus America INC. | $148.08 | 2024 | Endocapsule Recorder, Visiglide, Hanarostent Esophagus Tts(Ccc) |
| Boston Scientific Corporation | $147.81 | 2021 | |
| Phathom Pharmaceuticals, INC. | $119.67 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $115.38 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $114.07 | 2024-2025 | Ibsrela |
| Covidien LP | $109.31 | 2019 | |
| Lilly USA, LLC | $76.51 | 2025 | Omvoh |
| Gilead Sciences, INC. | $51.14 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $44.72 | 2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $39.59 | 2024 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $36.99 | 2024-2025 | Sucraid, Sucraid |
| Echosens North America, INC. | $32.41 | 2025 | Fibroscan |
| Aimmune Therapeutics, INC. | $24.26 | 2025 | Zenpep |
| Genzyme Corporation | $21.04 | 2025 | |
| Pfizer INC. | $17.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Alsayid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.